

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-5. (Cancelled)

6. (Currently Amended) A method for delivering a pharmaceutical composition comprising a nucleic acid to a tissue site of an animal or human, comprising the steps of:

providing a graspable gene delivery device comprising a contact surface;

applying said pharmaceutical composition to said contact surface; and

contacting said contact surface to said tissue site, wherein said contacting is by moving said contact surface across said tissue site,

~~The method according to claim 1,~~ wherein said gene delivery device comprises a lumen defining an opening such that fluid exiting said opening comes in contact with said contact surface, and wherein said applying comprises delivering said pharmaceutical composition through said opening to said contact surface.

7. (Currently Amended) A method for delivering a pharmaceutical composition comprising a nucleic acid to a tissue site of an animal or human, comprising the steps of:

providing a graspable gene delivery device comprising a contact surface;

applying said pharmaceutical composition to said contact surface; and

contacting said contact surface to said tissue site, wherein said contacting is by moving said contact surface across said tissue site,

~~The method according to claim 1 or 6,~~ wherein said pharmaceutical composition further comprises a polymerizable agent, which polymerizes when said contact surface is contacted to said tissue site.

8. (Currently Amended) A method for delivering a pharmaceutical composition comprising a nucleic acid to a tissue site of an animal or human, comprising the steps of:

providing a graspable gene delivery device comprising a contact surface;

applying said pharmaceutical composition to said contact surface; and

contacting said contact surface to said tissue site, wherein said contacting is by moving said contact surface across said tissue site.

~~The method according to claim 6,~~ wherein said lumen comprises a first and second channel sharing a common wall, and said method further comprises delivering a polymerizable compound through said first channel and a polymerizing agent through said second channel, and wherein said polymerizing agent is polymerized by said polymerizing agent at said tissue site.

9. (Original) A method according to claim 8, wherein said pharmaceutical composition is mixed with said polymerizable compound.

10. (Cancelled)

11. (Previously Presented) A kit, comprising:

a gene delivery device comprising a contact surface for contacting a tissue, wherein said contact surface comprises bristles; and

a pharmaceutical composition comprising a nucleic acid, a polymerizeable compound, and a polymerizing agent.

12. (Previously Presented) A kit, comprising:

a gene delivery device comprising a graspable surface for attachment to a contact surface;
at least one contact surface for attachment to said graspable surface, wherein said contact surface comprises bristles; and;

a pharmaceutical composition comprising a dye or other detectable moiety, a polymerizeable compound, a polymerizing agent, and a nucleic acid.

13. (Cancelled)

14. (Previously Presented) The kit according to claim 11 or 12, wherein said nucleic acid is DNA.

15. (Previously Presented) The kit according to claim 11 or 12, wherein said nucleic acid is RNA, an anti-sense molecule, a triple-helix-forming nucleic acid, an aptamer, or a ribozyme.

16. (Original) The kit according to claim 11 or 12, wherein said polymerizeable compound is fibrinogen and said polymerizing agent is thrombin.

17. (Previously Presented) The kit according to claim 11 or 12, wherein said gene delivery device comprises a graspable surface having a longitudinal axis, and said contact surface is detachable from said graspable element.

18. (Previously Presented) The kit according to claim 12, wherein said contact surface comprises a plurality of contact surfaces, each of which are differently angulated with respect to the longitudinal axis of the graspable surface.

19. (Previously Presented) The kit according to claim 11 or 12, wherein said gene delivery device further comprises a housing defining a lumen and having an opening such that fluid exiting said opening comes in contact with said contact surface, said lumen for delivering said pharmaceutical composition to a tissue site being contacted by the contact surface.

20. (Original) The kit according to claim 19, further comprising a double-barreled syringe and conduit-tubing.

21. (Cancelled)

22. (Currently Amended) A device for delivering a pharmaceutical composition to a tissue, comprising:

a housing having a first end and a second end and defining a lumen, said first end comprising an opening;

a contact surface for contacting a tissue, wherein said contact surface comprises a plurality of bristles at least partially surrounding said opening, wherein said contact surface is detachably connected to said first end of said housing, and

~~The device of claim 21,~~ wherein said contact surface is connected to said housing via an adapter.

23. (Currently Amended) A device for delivering a pharmaceutical composition to a tissue, comprising:

a housing having a first end and a second end and defining a lumen, said first end comprising an opening;

a contact surface for contacting a tissue, wherein said contact surface comprises a plurality of bristles at least partially surrounding said opening, wherein said contact surface is detachably connected to said first end of said housing, and

~~The device of claim 21,~~ wherein said contact surface is adjustable to an angle that is 0-180° angle with respect to the longitudinal axis of the housing.

24. (Currently Amended) A device for delivering a pharmaceutical composition to a tissue, comprising:

a housing having a first end and a second end and defining a lumen, said first end comprising an opening;

a contact surface for contacting a tissue, wherein said contact surface comprises a plurality of bristles at least partially surrounding said opening, wherein said contact surface is detachably connected to said first end of said housing, and

~~The device of claim 21,~~ wherein said lumen further comprises a first and second channel, said first and second channel sharing a common wall.

25. (Currently Amended) A device for delivering a pharmaceutical composition to a tissue, comprising:

a housing having a first end and a second end and defining a lumen, said first end comprising an opening;

a contact surface for contacting a tissue, wherein said contact surface comprises a plurality of bristles at least partially surrounding said opening, wherein said contact surface is detachably connected to said first end of said housing, and

~~The device of claim 21,~~ wherein said second end of said housing is connectable to a syringe or conduit-tubing.

26. (Previously Presented) The device of claim 25, wherein said syringe and conduit tubing are double-barreled.

27. (Currently Amended) A device for delivering a pharmaceutical composition to a tissue, comprising:

a housing having a first end and a second end and defining a lumen, said first end comprising an opening;

a contact surface for contacting a tissue, wherein said contact surface comprises a plurality of bristles at least partially surrounding said opening, wherein said contact surface is detachably connected to said first end of said housing, and

~~The device of claim 21,~~ wherein said first end comprises a plurality of openings.

28. (Cancelled)

29. (Currently Amended) A kit comprising a device for delivering a pharmaceutical composition to a tissue, and a pharmaceutical composition comprising a nucleic acid, wherein said device comprises:

a housing having a first end and a second end and defining a lumen, said first end comprising an opening;

a contact surface for contacting a tissue, wherein said contact surface comprises a plurality of bristles at least partially surrounding said opening, and wherein said contact surface is connected to said first end of said housing.

30-32. (Cancelled)

33. (Currently Amended) A device for delivering a pharmaceutical composition to a tissue, comprising:

a housing having a first end and a second end and defining a lumen, said first end comprising an opening;

a contact surface for contacting a tissue, wherein said contact surface comprises a plurality of bristles at least partially surrounding said opening, wherein said contact surface is connected to said first end of said housing, wherein said contact surface is adjustable to an angle that is 0-180° with respect to the longitudinal axis of said housing, and

~~The device of claim 31,~~ wherein said lumen further comprises a first and second channel, said first and second channel sharing a common wall.

34-35. (Cancelled)

36. (Currently Amended) A device for delivering a pharmaceutical composition to a tissue, comprising:

a housing having a first end and a second end and defining a lumen, said first end comprising an opening;

a contact surface for contacting a tissue, wherein said contact surface comprises a plurality of bristles at least partially surrounding said opening, wherein said contact surface is connected to said first end of said housing, wherein said contact surface is adjustable to an angle that is 0-180° with respect to the longitudinal axis of said housing, and

~~The device of claim 31,~~ wherein said first end comprises a plurality of openings.

37. (Previously Presented) The kit according to claim 29, wherein said nucleic acid is DNA.

38. (Previously Presented) The kit according to claim 29, wherein said nucleic acid is RNA, an anti-sense molecule, a triple-helix-forming nucleic acid, an aptamer, or a ribozyme.

39. (Previously Presented) The kit according to claim 29, wherein said contact surface is detachable from said housing.

40. (Previously Presented) The kit according to claim 29, wherein said contact surface comprises a plurality of contact surfaces, each of which are differently angulated with respect to the longitudinal axis of said housing.